{
    "clinical_study": {
        "@rank": "122720", 
        "arm_group": [
            {
                "arm_group_label": "PF-04937319 once-daily", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PF-04937319 split-dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sitagliptin once-daily", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Study B1621019 will assess efficacy and safety of two different dosing regimens of an\n      investigational agent (PF-04937319) compared to an approved drug (sitagliptin) in patients\n      with type 2 diabetes"
        }, 
        "brief_title": "Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with type 2 diabetes, on background metformin therapy either alone or with 1\n             other oral anti-diabetic agent (excluding Actos)\n\n        Exclusion Criteria:\n\n          -  Patients with cardiovascular event within 6-months of screening\n\n          -  Patients with diabetic complications\n\n          -  Female subjects who are pregnant or planning to become pregnant\n\n          -  Subjects with unstable medical conditions (eg, hypertension)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933672", 
            "org_study_id": "B1621019"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-04937319 once-daily", 
                "description": "Tablets, 300 mg once-daily with breakfast, 14-days", 
                "intervention_name": "PF-04937319 once-daily", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-04937319 split-dose", 
                "description": "tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days", 
                "intervention_name": "PF-04937319 split-dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sitagliptin once-daily", 
                "description": "tablets, 100 mg once-daily with breakfast, 14-days", 
                "intervention_name": "Sitagliptin once-daily", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sitagliptin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1b", 
            "type 2 diabetes", 
            "metformin background", 
            "PF-04937319"
        ], 
        "lastchanged_date": "April 1, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1621019&StudyName=Study%20Of%20Two%20Dosing%20Regimens%20Of%20PF-04937319%20Compared%20To%20An%20Approved%20Agent%20%28Sitagliptin%29%20In%20Patients%20With%20Type%202%20Diabetes"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "DeLand", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32720"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "High Point", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27265"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45255"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Bend", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53095"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1b, Randomized, Double-Blind, Active Comparator Controlled, 3-Period, Cross-Over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of PF-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "AUC is a measure of plasma glucose levels over time; used to characterize anti-diabetic effect of drug", 
            "measure": "Any Effects: Area Under Effect Curve (AUE) From 0-X Hour", 
            "safety_issue": "No", 
            "time_frame": "Day 1 and Day 14 of each period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933672"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Effect of drug on fasting plasma glucose", 
                "measure": "fasting plasma glucose", 
                "safety_issue": "No", 
                "time_frame": "Day 0, 1, 13, 14"
            }, 
            {
                "description": "pre-breakfast, pre-lunch, pre-dinner levels of plasma insulin", 
                "measure": "pre-meal insulin", 
                "safety_issue": "No", 
                "time_frame": "Day 0 and Day 14"
            }, 
            {
                "description": "pre-breakfast, pre-lunch, pre-dinner levels of serum C-peptide", 
                "measure": "pre-meal C-peptide", 
                "safety_issue": "No", 
                "time_frame": "Day 0 and Day 14"
            }, 
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "AUC(0-24) = area-under-drug-concentration curve from zero to 24hrs post AM dose", 
                "measure": "Area Under the Curve From Time Zero to 24hrs", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "measure": "Minimum Observed Plasma Trough Concentration (Cmin)", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}